PPARG and influenza: We then addressed whether activation of PPARγ by a commercial agonist would reduce the proinflammatory response in human AMs in vitro and protect infected mice from severe lung injury and inflammation in vivo. We demonstrated that influenza infection impaired PPARγ signaling, which led to an excessive proinflammatory response in human AMs but not in epithelial cells and lung inflammation and pathology in vivo.